Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 15, 2008, Pages 4339-4343

  Akwabi Ameyaw, Adwoa ^a   Bass, Jonathan Y ^a   Caldwell, Richard D ^a   Caravella, Justin A ^a   Chen, Lihong ^a   Creech, Katrina L ^a   Deaton, David N ^a   Jones, Stacey A ^a   Kaldor, Istvan ^a   Liu, Yaping ^a   Madauss, Kevin P ^a   Marr, Harry B ^a   McFadyen, Robert B ^a   Miller, Aaron B ^a   III, Frank Navas ^a   Parks, Derek J ^a   Spearing, Paul K ^a   Todd, Dan ^a   Williams, Shawn P ^a   Wisely, G Bruce ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Bile acid receptor; Farnesoid X receptor agonist; FXR; FXR X ray co crystal structure; GSK8062; GW 4064; Naphthoic acid; NR1H4; Nuclear receptor modulator

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; FARNESOID X RECEPTOR AGONIST; GSK 8062; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHOLESTASIS; DISEASE SEVERITY; MOUSE; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; CARBOXYLIC ACIDS; CHOLESTASIS; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOGS; HAPLORHINI; ISOXAZOLES; MICE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NAPHTHALENES; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STOMACH; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

RATTUS;

EID: 47749128054     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.073     Document Type: Article

References (41)

1. Zhang Y., and Edwards P.A. FEBS Lett. 582 (2008) 10
2. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., and Shanz B. Science 284 (1999) 1362
3. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., and Lehmann J.M. Science 284 (1999) 1365
4. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., and Weinberger C. Cell 81 (1995) 687
5. Higashiyama H., Kinoshita M., and Asano S. Acta Histochem. 110 (2008) 86
6. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., and Gonzalez F.J. Cell 102 (2000) 731
7. Rizzo G., Renga B., Mencarelli A., Pellicciari R., and Fiorucci S. Curr. Drug Targets: Immune, Endocr. Metab. Disord. 5 (2005) 289
8. Maloney P.R., Parks D.J., Haffner C.D., Fivush A.M., Chandra G., Plunket K.D., Creech K.L., Moore L.B., Wilson J.G., Lewis M.C., Jones S.A., and Willson T.M. J. Med. Chem. 43 (2000) 2971
9. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., Moore D.D., and Auwerx J. J. Clin. Invest. 113 (2004) 1408
10. Lambert G., Amar M.J.A., Guo G., Brewer Jr. H.B., Gonzalez F.J., and Sinal C.J. J. Biol. Chem. 278 (2003) 2563
11. Zhang Y., Lee F.Y., Barrera G., Lee H., Vales C., Gonzalez F.J., Willson T.M., and Edwards P.A. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 1006
12. Ma K., Saha P.K., Chan L., and Moore D.D. J. Clin. Invest. 116 (2006) 1102
13. Cariou B., van Harmelen K., Duran-Sandoval D., van Dijk T., Grefhorst A., Bouchaert E., Fruchart J.-C., Gonzalez F.J., Kuipers F., and Staels B. FEBS Lett. 579 (2005) 4076
14. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J., and Kliewer S.A. Cell Metab. 2 (2005) 217
15. Inagaki T., Moschetta A., Lee Y.-K., Peng L., Zhao G., Downes M., Yu R.T., Shelton J.M., Richardson J.A., Repa J.J., Mangelsdorf D.J., and Kliewer S.A. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 3920
16. Jung D., Inagaki T., Gerard R.D., Dawson P.A., Kliewer S.A., Mangelsdorf D.J., and Moschetta A. J. Lipid Res. 48 (2007) 2693
17. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., and Moore D.D. Science 312 (2006) 233
18. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., Mansfield T.A., Kliewer S.A., Goodwin B., and Jones S.A. J. Clin. Invest. 112 (2003) 1678
19. Fiorucci S., Clerici C., Antonelli E., Orlandi S., Goodwin B., Sadeghpour B.M., Sabatino G., Russo G., Castellani D., Willson T.M., Pruzanski M., Pellicciari R., and Morelli A. J. Pharmacol. Exp. Ther. 313 (2005) 604
20. Stedman C., Liddle C., Coulter S., Sonoda J., Alvarez J.G., Evans R.M., and Downes M. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 11323
21. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., and Morelli A. Gastroenterology 127 (2004) 1497
22. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Morelli A., Pruzanski M., and Pellicciari R. J. Pharmacol. Exp. Ther. 315 (2005) 58
23. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pruzanski M., Morelli A., and Pellicciari R. J. Pharmacol. Exp. Ther. 314 (2005) 584
24. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., and Gonzalez F.J. Carcinogenesis 28 (2007) 940
25. Yang F., Huang X., Yi T., Yen Y., Moore D.D., and Huang W. Cancer Res. 67 (2007) 863
26. Hanniman E.A., Lambert G., McCarthy T.C., and Sinal C.J. J. Lipid Res. 46 (2005) 2595
27. Zhang Y., Wang X., Vales C., Lee F.Y., Lee H., Lusis A.J., and Edwards P.A. Arterioscler. Thromb., Vasc. Biol. 26 (2006) 2316
28. Moschetta A., Bookout A.L., and Mangelsdorf D.J. Nat. Med. 10 (2004) 1352
29. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., Morelli A., Parks D.J., and Willson T.M. J. Med. Chem. 45 (2002) 3569
30. Downes M., Verdecia M.A., Roecker A.J., Hughes R., Hogenesch J.B., Kast-Woelbern H.R., Bowman M.E., Ferrer J.-L., Anisfeld A.M., Edwards P.A., Rosenfeld J.M., Alvarez J.G.A., Noel J.P., Nicolaou K.C., and Evans R.M. Mol. Cell 11 (2003) 1079
31. Kuo C.H., Hook J.B., and Bernstein J. Toxicology 22 (1981) 149
32. Sugihara K., Kitamura S., Sanoh S., Ohta S., Fujimoto N., Maruyama S., and Ito A. Toxicol. Appl. Pharmacol. 167 (2000) 46
33. Deaton, D. N.; McFadyen, R. B.; Navas, F., III; Caldwell, R.; Spearing, P. K. PCT Int. Appl. WO 076260, 2007.
34. Deaton D.N., McFadyen R.B., Navas III F., Caldwell R., and Spearing P.K. Chem. Abstr. 147 (2007) 143407
35. Morand, E. F.; Iskander, M.N. PCT Int. Appl. WO 104178, 2003
36. Morand E.F., and Iskander M.N. Chem. Abstr. 140 (2003) 27670
37. Although methyl 7-hydroxy-2-naphthoate 3c is known in the literature, it was prepared from commercially available 7-methoxy-2-naphthol in three synthetic steps. First, 7-methoxy-2-naphthol was converted into the triflate with trifluoromethanesulfonic anhydride. Then, palladium-mediated carbonylation of the triflate under a carbon monoxide atmosphere in methanol and N,N-dimethylformamide provided methyl 7-methoxy-2-naphthoate. Finally, cleavage of the methyl ether with boron tribromide gave the desired methyl 7-hydroxy-2-naphthoate 3c.
38. Anderson L.C., and Thomas D.G. J. Am. Chem. Soc. 65 (1943) 234
39. Lu Y.-H., Luo X.-H., and Yang C.-L. Ranliao Yu Ranse 42 (2005) 34
40. 741-761SRC-1, K-E-S-K-D-H-Q-L-L-R-Y-L-L-D-K-D-E-K-D-L-R) derived from steroid receptor coactivator-1 (SRC-1) was added to 1.5 mol protein equivalents and incubated on ice for another hour. The protein complexes were concentrated to 12 mg/ml or higher and crystallized by hanging drop vapor diffusion around the conditions 0.1 M Bis(2-hydroxyethyl)-imino-tris(hydroxymethyl)-methane, pH 6.5, 0.2 M lithium sulfate, and 20% polyethylene glycol 4000. The crystals were frozen by stepwise exchange into the same buffer, with 30% glycerol, followed by plunging into liquid nitrogen.
41. Mi L.-Z., Devarakonda S., Harp J.M., Han Q., Pellicciari R., Willson T.M., Khorasanizadeh S., and Rastinejad F. Mol. Cell 11 (2003) 1093